Drugs / Plitidepsin
Plitidepsin
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04382066 | May → Nov 2020 | COVID-19 | PharmaMar | Completed | No outcome recorded |
| Phase 1 | NCT02100657 | Jun 2014 → Jun 2018 | plasma cell myeloma | PharmaMar | Completed | No outcome recorded |
| Phase 1 | NCT00788099 | Dec 2008 → Jun 2011 | cancer, lymphoma | PharmaMar | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05121740 | Jan → Mar 2022 | COVID-19 | PharmaMar | Completed | No outcome recorded |
| Phase 1/2 | NCT00780143 | Nov 2007 → Jun 2009 | leukemia | PharmaMar | Terminated | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06766825 | Feb 2025 → Sep 2026 expected | long COVID-19 | Fight AIDS and Infectious Diseases Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05705167 | Apr 2023 → Mar 2024 | COVID-19 | PharmaMar | Terminated | No outcome recorded |
| Phase 2 | NCT03117361 | May 2017 → Jul 2018 | plasma cell myeloma | PharmaMar | Terminated | No outcome recorded |
| Phase 2 | NCT03070964 | Oct 2016 → Jul 2018 | lymphoma | PharmaMar | Terminated | No outcome recorded |
| Phase 2 | NCT01876043 | Feb 2012 → Apr 2015 | dedifferentiated liposarcoma | Institut Bergonié | Terminated | No outcome recorded |
| Phase 2 | NCT01149681 | Jul 2010 → Feb 2011 | myelofibrosis | PharmaMar | Completed | No outcome recorded |
| Phase 2 | NCT00780975 | Feb 2005 → Mar 2008 | prostate cancer | PharmaMar | Terminated | No outcome recorded |
| Phase 2 | NCT00229203 | Feb 2005 → Aug 2008 | plasma cell myeloma | PharmaMar | Completed | No outcome recorded |
| Phase 2 | NCT00884286 | Dec 2004 → Jun 2010 | leukemia, lymphoma | PharmaMar | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04784559 | Jun 2021 → Mar 2023 | COVID-19 | PharmaMar | Terminated | No outcome recorded |
| Phase 3 | NCT01102426 | Jun 2010 → Nov 2017 | refractory plasma cell neoplasm | PharmaMar | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | plitidepsin | “Aplidin (plitidepsin)” NCT00780975 ↗ |
| Known as | Aplidin | “Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide” NCT03117361 ↗5“Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia” NCT00780143 ↗ “Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma” NCT02100657 ↗ “Drug: APLIDIN (plitidepsin)” NCT01149681 ↗ |
| Known as | APLIDIN (plitidepsin) | “APLIDIN (plitidepsin)” NCT01102426 ↗ |
| Action | Inhibit | “Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A.” PMID 35012962 ↗ Jan 2022 |
| Modality | Peptide | “Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A.” PMID 35012962 ↗ Jan 2022 |
| Route | Intravenous | “Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks” NCT00229203 ↗ |